INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Reference |
|---|
| "Chronic hepatitis C is a slowly progressive liver disease that may evolve into cirrhosis with its potential complications of liver failure or hepatocellular carcinoma." | ( Brouwer, JT; de Man, RA; Schalm, SW; van Rossum, TG; Vulto, AG, 1998) |
| "Chronic hepatitis C is a major health care problem throughout the world." | ( Moussalli, J; Opolon, P; Poynard, T, 1998) |
| "Chronic hepatitis C is often associated with liver iron overload, which may affect the long-term prognosis and the response to antiviral treatment." | ( Baud, M; Beris, P; Giostra, E; Hadengue, A; Male, PJ; Negro, F; Quadri, R; Rubbia-Brandt, L; Samii, K; Zarski, JP, 2000) |
| "Liver failure from chronic hepatitis C is the leading indication for liver transplantation in the United States." | ( Carithers, RL; Chang, M; Cotler, SJ; Gretch, DR; Marquardt, AP; Taylor, SL; Williams, O; Wood, BL, 2000) |
| "The treatment of chronic hepatitis C is aimed at eliminating viral replication in order to prevent further evolution towards cirrhosis and hepatocellular carcinoma." | ( Gretch, DR; Pawlotsky, JM, 1998) |
| "Cirrhosis caused by chronic hepatitis C is now the most common indication for liver transplantation." | ( Davis, GL, 2000) |
| "Chronic hepatitis C is a major long-term problem for children who survive cancer." | ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Preisegger, KH; Schwinger, W; Urban, C, 2000) |
| "Chronic hepatitis C is one of the leading causes of cirrhosis and end-stage liver cirrhosis; thus effective therapies are required." | ( Cornberg, M; Manns, MP; Wedemeyer, H, 2001) |
| "Chronic hepatitis C is the major cause of cirrhosis and hepatocellular carcinoma (HCC), which most often lead to liver transplantation." | ( Meier, V; Ramadori, G, 2001) |
| "Chronic hepatitis C is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide." | ( Blum, HE; Cerny, A; Heim, MH; Moradpour, D; Wölk, B, 2001) |
| "Treatment of chronic hepatitis C is a major problem." | ( van Hattum, J; van Soest, H, 2001) |
| "Patients with chronic hepatitis C are now treated with a combination of interferon alpha (IFN) and ribavirin." | ( Nĕmecek, V; Rýzlová, M; Stránský, J; Stríteský, J, 2002) |
| "Liver fibrosis in chronic hepatitis C is related to sex, age at infection, duration of infection, and alcohol consumption." | ( Charlotte, F; Imbert-Bismut, F; Myers, RP; Poynard, T; Ratziu, V, 2002) |
| "The treatment of chronic hepatitis C is currently based on a combination of pegylated interferon (IFN)-alpha and ribavirin." | ( Pawlotsky, JM, 2003) |
| "Chronic hepatitis C is a serious condition that can lead to cirrhosis of the liver, and may progress to life-threatening hepatocellular carcinoma." | ( Tsolakos, A; Zalatimo, N, 2003) |
| "Chronic hepatitis C is another risk factor for porphyria cutanea tarda." | ( Bonkovsky, HL; Lambrecht, RW; Shan, Y, 2003) |
| "Cirrhosis due to chronic hepatitis C is now the leading indication for liver transplantation in the United States." | ( Everson, GT, 2004) |
| "Chronic hepatitis C is frequently associated with increased hepatic iron stores." | ( Bosserhoff, AK; Brügmann, M; Dietrich, CG; Gartung, C; Geier, A; Gressner, AM; Lammert, F; Lorenzen, J; Matern, S; Reugels, M; Siewert, E; Wasmuth, HE; Weiskirchen, R, 2004) |
| "Chronic hepatitis C is the leading cause of liver disease and liver-related mortality in the western world." | ( Vogel, W, 2003) |
| "Chronic hepatitis C is a leading cause of cirrhosis, hepatocellular carcinoma, digestive tract haemorrhage and hepatic insufficiency." | ( Poynard, T, 2004) |
| "Chronic hepatitis C is common and aggressive in HIV-positive patients, so the development of a well-tolerated HCV therapy is a priority." | ( Angeli, E; Cargnel, A; Duca, P; Giorgi, R; Gubertini, G; Mainini, A; Schiavini, M, 2005) |
| "Chronic hepatitis C is a major cause of morbidity and mortality in haemophilia patients." | ( Fischer, K; Makris, M; Mauser-Bunschoten, EP; Posthouwer, D, 2006) |
| "Chronic hepatitis C is often associated with oxidative stress." | ( Chan, SW; Egan, PA; Elliott, RM; Jack, SC; MacCallum, PR; McDermott, BT, 2006) |
| "Chronic hepatitis C is a major comorbidity in patients with haemophilia." | ( De Heusden, N; Fischer, K; Mauser-Bunschoten, EP; Posthouwer, D, 2007) |
| "Chronic hepatitis C is treated primarily with pegylated interferon (peg-IFN) and an inosine 5' monophosphate dehydrogenase inhibitor, ribavirin (RBV), with the goal of achieving a sustained virologic response (SVR)." | ( Kallman, J; Kincaid, J; Younossi, Z, 2007) |
| "Chronic hepatitis C is a major cause of cirrhosis and primary liver cancer (hepatocellular carcinoma)." | ( Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP, 2007) |
| "Chronic hepatitis C is a major contributor to cirrhosis and hepatocellular cancer worldwide, justifying the considerable research effort aimed at understanding the disease and refining its treatment." | ( Foster, G; Mathurin, P, 2008) |
| "Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy." | ( Abate, ML; Bo, S; Bugianesi, E; Cassader, M; Ciancio, A; Ciccone, G; Gambino, R; Giordanino, C; Olivero, A; Pellicano, R; Rizzetto, M; Saracco, G; Smedile, A, 2008) |
| "Chronic hepatitis C is associated with substantial morbidity and mortality and poses a considerable socioeconomic burden." | ( Smith, JP, 2008) |
| "Chronic hepatitis C is a leading cause of hepatocellular carcinoma (HCC) worldwide." | ( Ishikawa, T, 2008) |
| "Chronic hepatitis C is among the leading causes of chronic liver disease worldwide, with approximately 170 million people infected." | ( Asselah, T; Benhamou, Y; Marcellin, P, 2009) |
| "Chronic hepatitis C is often a progressive, fibrotic disease that can lead to cirrhosis and other complications." | ( Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K, 2008) |
| "Chronic hepatitis C is frequent and aggressive in HIV-positive patients." | ( Andreoni, M; Angeli, E; Carbone, R; Cargnel, A; Giorgi, R; Gubertini, G; Mainini, A; Orani, A; Rizzardini, G; Schiavini, M; Uberti-Foppa, C, 2009) |
| "Chronic hepatitis C is a major worldwide health problem with an estimated prevalence of 1." | ( Aghemo, A; Colombo, M; Rumi, MG, 2009) |
| "Chronic hepatitis C is a major health concern." | ( Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E, 2009) |
| "Chronic hepatitis C is generally underappreciated in Asian Americans, and most pivotal studies were conducted in western countries and only included a small numbers of Asian patients." | ( Garcia, RT; Levitt, B; Nguyen, H; Nguyen, K; Nguyen, MH; Nguyen, NH; Trinh, H; VuTien, P, 2010) |
| "Chronic hepatitis C is one of the leading causes for chronic liver disease globally." | ( Mac Nicholas, R; Norris, S, 2010) |
| "Chronic hepatitis C is an emerging issue in the management of human immunodeficiency virus (HIV) disease because both diseases have the same route of transmission, leading to a very high prevalence of hepatitis C virus (HCV)-coinfection in the HIV-positive patient population." | ( Calza, L; Colangeli, V; Erario, A; Grossi, G; Manfredi, R; Mosca, L; Piergentili, B; Pocaterra, D; Verucchi, G; Viale, P, 2011) |
| "Chronic hepatitis C is associated with an increased prevalence of insulin resistance, which might result from liver disease, metabolic factors, or the hepatitis C virus (HCV) itself." | ( Afdhal, N; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Howell, CD; Wahed, AS, 2011) |
| "Chronic hepatitis C is associated with cirrhosis, hepatic failure, and death; therefore, treatment is aimed at reducing these complications, as well as improving quality of life and minimizing adverse effects." | ( Ferguson, MC, 2011) |
| "Chronic hepatitis C is one of the leading causes of chronic liver disease, with approximately 170 million people infected worldwide." | ( Asselah, T; Marcellin, P, 2011) |
| "Chronic hepatitis C is one of the major causes of end-stage liver disease with a high incidence rate, amounting to a grave and serious problem of public health." | ( Chen, JJ; Gao, YQ; Nie, HM, 2011) |
| "Chronic hepatitis C is one of the leading causes of chronic liver disease with approximately 170 million people infected worldwide." | ( Asselah, T; Marcellin, P, 2012) |
| "Chronic hepatitis C is an independent risk factor for severe drug hepatotoxicity." | ( Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Krastinova, E; Perronne, C; Piroth, L; Pol, S; Quertainmont, Y; Rosenthal, E, 2012) |
| "Today, treatment of chronic hepatitis C is based on a synergistic combination of pegylated interferon and ribavirin with antiprotease inhibitors." | ( Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN, 2012) |
| "The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin." | ( Gara, N; Ghany, MG, 2013) |
| "Chronic hepatitis C is an important health problem in Chile." | ( Aravena, E; González, MZ; Iturriaga, H; Pinto, A; Roblero, JP, 2012) |
| "Chronic hepatitis C is the leading cause of chronic liver disease, representing a significant burden in terms of morbidity, mortality and costs." | ( Blázquez-Pérez, A; Mar, J; San Miguel, R, 2013) |
| "Chronic hepatitis C is one of the liver diseases that show hepatic iron accumulation, even though its level should be recognized to be basically mild to moderate and sometimes within the normal range." | ( Hara, Y; Hino, K; Nishina, S, 2013) |
| "Resolution of chronic hepatitis C is considered when serum HCV RNA becomes repeatedly undetectable and liver enzymes normalize." | ( Chauhan, R; Chen, AY; Jacobson, IM; Michalak, TI; Talal, AH; Zeremski, M, 2013) |
| "The treatment of chronic hepatitis C is changing rapidly." | ( Koff, RS, 2014) |
| "Chronic hepatitis C is a leading cause of liver-related mortality and morbidity." | ( Gluud, C; Grevstad, B; Jakobsen, JC; Nikolova, K, 2014) |
| "Chronic hepatitis C is a global health problem." | ( Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M, 2014) |
| "Chronic hepatitis C is a public health problem worldwide." | ( Cipăian, RC; Mihăilă, RG, 2014) |
| "Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide." | ( Kattakuzhy, S; Kottilil, S; Levy, R, 2015) |
| "Treating chronic hepatitis C is crucial to preventing long-term complications such as cirrhosis and liver cancer." | ( Murfin, M, 2015) |
| "Chronic hepatitis C is commonly associated with extrahepatic manifestations." | ( Bellanti, F; Lauletta, G; Lipsi, MR; Natalicchio, MI; Sansonno, D; Serviddio, G; Vendemiale, G; Villani, R, 2015) |
| "Patients with chronic hepatitis C are expected to receive this treatment worldwide." | ( Rino, Y; Yamamoto, N; Yukawa, N, 2015) |
| "Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma." | ( Bernuth, S; Galle, PR; Kittner, JM; Knapstein, J; Schad, A; Schattenberg, JM; Schuppan, D; Sprinzl, MF; Weyer, V; Wörns, MA; Yagmur, E; Zimmermann, A; Zimmermann, T, 2016) |
| "The treatment of chronic hepatitis C is revolutionizing rapidly." | ( Kao, JH; Yang, SS, 2016) |
| "Chronic hepatitis C is an important public health problem in Asia." | ( Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J, 2016) |
| "Chronic hepatitis C is common in people who inject drugs (PWID) and this population serves as a reservoir for infection." | ( Axten, D; Dalton, J; Foster, GR; Gardner, H; Kunkel, J; Lewis, H; Tippett, A; Wilkinson, M; Wynne, S, 2016) |
| "Chronic hepatitis C is a global health problem." | ( Azzari, C; Cananzi, M; D'Antiga, L; Grisotto, L; Indolfi, G; Maccabruni, A; Nebbia, G; Resti, M; Zaramella, M, 2016) |
| "The condition of chronic hepatitis C is becoming more and more serious in China, and its disease burden and social and economic burdens are growing heavier." | ( Hu, P; Ren, H, 2016) |
| "Chronic hepatitis C is a viral infection causing chronic inflammation of liver tissue (hepatitis) which ultimately progresses to fibrosis and liver cirrhosis with a high chance of hepatocellular carcinoma." | ( Ananyan, S; Gemilyan, M; Hakobyan, G, 2018) |
| "Patients with chronic hepatitis C are often complicated by chronic kidney disease (CKD)." | ( Abe, H; Aizawa, Y; Akahane, T; Atsukawa, M; Fukunishi, S; Genda, T; Hotta, N; Ikegami, T; Iwakiri, K; Kondo, C; Kumada, T; Michitaka, K; Nakamuta, M; Nozaki, A; Ogawa, C; Shima, T; Shimada, N; Tachi, Y; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T, 2019) |
| Excerpt | Reference |
|---|
| "Interferon-alpha treatment of chronic hepatitis C is beneficial in only 20-30% of patients." | ( Casalino, C; Genchi, C; Mariano, N; Maselli, R; Milella, M; Pastore, G; Pietromatera, G; Santantonio, T, 1999) |
| "The clinical features and treatment of chronic hepatitis C in Chinese patients are the same as in Caucasian patients except that 27% of Chinese chronic hepatitis C patients have hepatitis C virus (HCV) genotype 6a." | ( Lai, CL, 1999) |
| "During treatment of chronic hepatitis C, interferon alpha induces thyroid dysfunctions (3 to 15% of the cases) with various clinical presentations." | ( Bailly, F; Broussolle, C; Steineur, MP; Trépo, C; Zoulim, F, 1999) |
| "There are no remarkably effective treatments for chronic hepatitis C in general use." | ( Berkson, BM, 1999) |
| "The major objective of treatment of chronic hepatitis C virus (HCV) infection is to prevent progression to cirrhosis, and thereby prevent complications of end-stage liver disease." | ( Barnes, E; Dusheiko, G; Jacobs, R; Webster, G, 1999) |
| "Data suggest that treating chronic hepatitis C in HIV-co-infected patients can decrease fibrosis, increase T-cell responsiveness to HCV antigens, and decrease the rate of fatal hepatomas." | ( Dieterich, DT, 1999) |
| "In the initial treatment of chronic hepatitis C, interferon-alfa (IFN-alpha) monotherapy for 24-48 weeks induces sustained response rates of only 10-20%." | ( Lai, MY, 2000) |
| "Standard treatment for chronic hepatitis C is with interferon (IFN)-alpha and ribavirin for 6-12 months." | ( Andersson, J; Bruchfeld, A; Schvarcz, R; Ståhle, L, 2001) |
| "For etiological treatment of chronic hepatitis C, eradication of persistent HCV infection is needed." | ( Kiyosawa, K; Sodeyama, T, 2001) |
| "Interferon-alpha was the first accepted treatment of chronic hepatitis C." | ( Elkabes, B; Saner, G; Sökücü, S; Süoğlu D, OD, 2002) |
| "In the past ten years, treatment of chronic hepatitis C has made great advances." | ( Zeuzem, S, 2002) |
| "The best treatment for chronic hepatitis C patients who do not respond to interferon is still unknown." | ( Battezzati, PM; Bissoli, F; Borzio, M; Bruno, S; Ceriani, R; Chiesa, A; Crosignani, A; Fargion, S; Fiorelli, G; Fracanzani, AL; Maraschi, A; Morini, L; Orlandi, A; Podda, M, 2003) |
| "Thus, the role of ketoprofen in the treatment of chronic hepatitis C needs to be further evaluated against such a treatment." | ( Andreone, P; Bernardi, M; Biselli, M; Cursaro, C; Di Giammarino, L; Felline, F; Fiorino, S; Galli, S; Gramenzi, A; Loggi, E; Lorenzini, S; Porzio, F, 2003) |
| "The current standard of treatment of chronic hepatitis C infection is the combination therapy of pegylated interferon plus ribavirin for 48 weeks for genotype 1 and 4 and 24 weeks for genotype 2 and 3." | ( Al-Kayyal, BM; Shobokshi, OA; Tantawe, AO, 2003) |
| "Patients in need of treatment for chronic hepatitis C should have a baseline fundus examination before initiating treatment to identify any pre-existing retinopathy." | ( Tsolakos, A; Zalatimo, N, 2003) |
| "Interferon-based regimens for the treatment of chronic hepatitis C have become increasingly effective and are able to eradicate virus in more than one half of cases." | ( Albrecht, J; Davis, GL; Harvey, J; Manns, MP; McHutchison, JG; Wong, JB, 2003) |
| "Despite advances in the treatment of chronic hepatitis C virus (HCV), the disease persists after treatment with interferon and ribavirin in a large percentage of patients and other therapeutic options are lacking." | ( Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C, 2003) |
| "In the absence of antiviral treatment, chronic hepatitis C virus (HCV) infection is a liver disease characterized by the development of necroinflammatory changes and progressive liver fibrosis, leading to cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC)." | ( García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M, 2003) |
| "In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon alpha-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon alpha-2b plus ribavirin, but it is still unproven whether this increase is cost effective." | ( Alberti, A; Craxi, A; De Carli, C; Giuliani, G; Green, J; Patel, KK; Sullivan, SD; Wintfeld, N, 2004) |
| "Strategies for the diagnosis and treatment of chronic hepatitis C continue to evolve." | ( Ahmed, A; Keeffe, EB, 2003) |
| "There is room for improvement in the treatment of chronic hepatitis C with standard interferon (IFN) alfa." | ( Brillanti, S, 2004) |
| "Despite important gains in treating chronic hepatitis C, many treatment challenges remain." | ( McHutchison, JG; Patel, K, 2004) |
| "Despite improvements in the treatment of chronic hepatitis C virus (HCV) infection, nearly half of all patients do not respond to initial therapy." | ( Shiffman, ML, 2004) |
| "All HIV-infected patients who had been treated for chronic hepatitis C at our institution and had a minimum follow-up of 6 months after discontinuing therapy were retrospectively analysed." | ( Barreiro, P; García-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Núñez, M; Soriano, V, 2004) |
| "Major progress has been made in the treatment of chronic hepatitis C virus (HCV) infection over the 18 years since Hoofnagle et al." | ( Afdhal, N; Kelleher, TB, 2005) |
| "A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution." | ( Chambers, TJ; Dibisceglie, AM; Droll, DA; Dustin, LB; Fan, X; Hembrador, E; Nickells, MW; Slater, T, 2005) |
| "Interferons play the main role in the treatment of chronic hepatitis C." | ( Andrejczyn, M; Halota, W; Pawłowska, M, 2004) |
| "Current guidelines for stopping treatment of chronic hepatitis C are based on hepatitis C ribonucleic acid measurements at 12 and 24 weeks." | ( de Knegt, RJ; Eijkemans, MJ; Habbema, JD; Hansen, BE; Schalm, SW; Stijnen, T; Veldt, BJ, 2005) |
| "All HIV-infected patients treated for chronic hepatitis C at our institution with a minimum follow-up of 6 months after discontinuing therapy were retrospectively analysed." | ( Barreiro, P; García-Samaniego, J; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Romero, M; Sánchez-Conde, M; Soriano, V, 2005) |
| "The main principle in treating chronic hepatitis C is the prevention of serious liver complications." | ( Gross, JB, 2005) |
| "Interferon (IFN)-based regimens for the treatment of chronic hepatitis C virus (HCV) infection have become increasingly effective and are able to eradicate virus in more than one half of treated individuals." | ( Afdhal, NH; Curry, MP, 2005) |
| "The evolution of treatment of chronic hepatitis C virus infection has led to improved therapeutic efficacy." | ( Casillas-Davila, L; Chirino-Sprung, R; Dehesa-Violante, M; Díaz-Hernandez, M; Juarez-Navarro, A; Navarro, JM; Vera-de-León, L, 2005) |
| "To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable." | ( Bläckberg, J; Carlsson, T; Norkrans, G; Reichard, O; Sangfelt, P; Wallmark, E; Weiland, O, 2005) |
| "Beside substantial progress in treatment of chronic hepatitis C (CHC) particular patients (genotype 1/4, high viral load, previous nonresponse, cirrhosis) remain difficult to treat." | ( Azzaroli, F; Bacchi Reggiani, ML; Brillanti, S; Colecchia, A; Feletti, V; Giovanelli, S; Lodato, F; Mazzella, G; Montagnani, M; Muratori, R; Roda, E; Tamé, MR, 2005) |
| "Immune-based therapy is the mainstay treatment for chronic hepatitis C virus (HCV) infection but causes multiple side effects and achieves durable viral clearance in only approximately 50% of patients." | ( Averett, DR; Bauman, LA; Berg, T; Desager, JP; Fletcher, SP; Horsmans, Y; Kerr, BM; Mueller, T; Schott, E; Steffy, KR, 2005) |
| "The only approved treatment of chronic hepatitis C are interferon (IFN) alfa-based regimens." | ( Simon, K; Szymczak, A, 2005) |
| "Despite recent advances in the treatment of chronic hepatitis C, especially introduction of combined therapy with pegylated interferons with ribavirin, significant number of patients fails to achieve sustained virologic response." | ( Pawłowska, M, 2005) |
| "Consensus guidelines are in place for treating chronic hepatitis C virus infection." | ( Sulkowski, MS, 2005) |
| "Impressive gains have been made in the treatment of chronic hepatitis C virus (HCV) infection during the past decade." | ( Ostojić, R, 2005) |
| "In the treatment of chronic hepatitis C genotype 1b infection, peginterferon and ribavirin combination therapy was introduced, and this combination therapy has been shown to induce 50% sustained virological response (SVR)." | ( Izumi, N, 2006) |
| "Despite of significant progress in the treatment of chronic hepatitis C after introduction of combination therapy with pegylated form of interferon-a with ribavirin, still overall response rate in HCV genotype-1 infected has been modest." | ( Juszczyk, J, 2006) |
| "There is yet no established treatment for chronic hepatitis C patients non-responder to standard interferon and ribavirin." | ( Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M, 2006) |
| "Interferon (IFN) is now the standard treatment for chronic hepatitis C (CH-C); however, treatment efficacy is unpredictable before IFN therapy is started." | ( Honda, H; Honda, M; Kaneko, S; Kawamura, T; Tateno, M, 2007) |
| "The overarching goal in treating chronic hepatitis C (CHC) is the prevention of serious hepatic complications such as cirrhosis, end-stage liver disease and hepatocellular carcinoma." | ( Bourlière, M; Pol, S, 2006) |
| "Successful treatment of chronic hepatitis C requires an understanding of the intricacies of this relationship and appropriate management of treatment-related symptoms." | ( Kallman, J; Kincaid, J; Younossi, Z, 2007) |
| "Standard treatment of chronic hepatitis C virus (HCV) infection based on interferon is not an option in renal transplant recipients due to the high risk of acute allograft rejection." | ( Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP, 2007) |
| "Amongst people on opioid maintenance treatment (OMT), chronic hepatitis C (HCV) is common but infrequently treated." | ( Conigrave, KM; Haber, PS; Wallace, C; Watson, B; Whitfield, JB; Wurst, F, 2007) |
| "Transaminase elevations during treatment of chronic Hepatitis C virus with pegylated interferon and ribavirin are common but rarely severe." | ( Hubscher, S; Lai, WK; Mutimer, D; O'Donnell, K; Thorburn, D; Thurairajah, PH; White, A, 2007) |
| "During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described." | ( Buntinx, F; De Bie, J; Robaeys, G; Van Ranst, M, 2007) |
| "As novel agents to treat chronic hepatitis C may not be accessible in the coming years on a broader scale for HIV-co-infected patients the use of higher ribavirin doses and longer treatment periods should be systematically studied to improve hepatitis C therapy in co-infected patients in the near future." | ( Mauss, S, 2007) |
| "There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA." | ( Buti, M; Casado, MA; Esteban, R, 2007) |
| "In the future there are planned treatment of chronic hepatitis C with combined therapy with IFN, specific HCV-enzymes inhibitors and antiviral medications." | ( Halota, W; Pawłowska, M, 2007) |
| "The gold standard treatment of chronic hepatitis C (CHC) is combined pegylated interferon and ribavirin." | ( Asselah, T; Bieche, I; Boyer, N; Laurendeau, I; Marcellin, P; Martinot-Peignoux, M; Narguet, S; Ripault, MP; Sabbagh, A; Valla, D; Vidaud, M, 2008) |
| "The standard treatment for chronic hepatitis C patients infected with HCV genotype-2 is a combination of pegylated interferon alfa and ribavirin over a 24 week period." | ( Jee, SR; Jung, EU; Kang, SW; Lee, SH; Lee, YJ; Pae, KI; Park, ET; Park, JH; Park, SJ; Seol, SY, 2007) |
| "To study the specific impact of treatments for chronic hepatitis C virus (HCV) infection on anger expression and control in adult patients coinfected with HIV and HCV receiving antiretroviral therapy." | ( Blanc, D; Carrieri, MP; Dellamonica, P; Marcellin, F; Préau, M; Ravaux, I; Spire, B, 2008) |
| "In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients." | ( Azuma, K; Enjoji, M; Furusyo, N; Hayashi, J; Kajiwara, E; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y, 2008) |
| "Interferon therapy is indicated for the treatment of chronic hepatitis C and prevention of hepatocellular carcinoma." | ( Benini, MC; Biagini, MR; Capanni, M; Colagrande, S; Lorefice, E; Milani, S; Salvadori, E; Surrenti, C; Tozzi, A, 2008) |
| "These data suggest that treatment of chronic hepatitis C patients with an HCV NS3." | ( Dijkgraaf, MG; Forestier, N; Gelderblom, HC; Jansen, PL; Mcnair, L; Purdy, S; Reesink, HW; Weegink, CJ; Zeuzem, S, 2008) |
| "Reluctance has been expressed about treating chronic hepatitis C in active intravenous (IV) drug users (IDUs), and this is found in both international guidelines and routine clinical practice." | ( Bruggmann, P; Dober, S; Falcato, L; Helbling, B; Keiser, O; Meili, D; Negro, F, 2008) |
| "Liver histological improvement after treatment for chronic hepatitis C in patients co-infected with human immunodeficiency virus-1 (HIV-1) has been described." | ( Castro, G; Figueiredo, JF; Martinelli, Ade L; Ramalho, LN; Zucoloto, S, 2008) |
| "Antiviral treatment in chronic hepatitis C (CHC) involves ribavirin, a hemolytic agent." | ( Abbati, G; Belussi, F; Bonetto, S; Boninsegna, S; Borghi, A; Carbonieri, A; Corradini, E; Fagiuoli, S; Fattovich, G; Felder, M; Ferrara, F; Ferrari, C; Guido, M; Massari, M; Minola, E; Orlandini, A; Pietrangelo, A; Pozzato, G; Rizzo, G; Rossi, E; Rovere, P; Sardini, C; Tagliazucchi, M; Toniutto, P; Vegetti, A; Ventura, P; Zeneroli, ML, 2009) |
| "The issue of best treatment for chronic hepatitis C virus (HCV) infection is in constant flux, not only in Western countries but also in Asia." | ( Chuang, WL; Yu, ML, 2009) |
| "The standard regimen for the treatment of chronic hepatitis C virus (HCV) is peginterferon alpha-2a or -2b associated with ribavirine." | ( Couzigou, VP; DeLedinghen, V; Foucher, J; Gaundong Mbéthé, GL, 2009) |
| "Standard of care (SOC) treatment for chronic hepatitis C (CHC) involves weekly pegylated (PEG) interferon plus weight-based ribavirin with resultant sustained virologic response (SVR) rates at or near 50% for genotypes 1 and 4 virus." | ( An, JW; Brady, DE; Harrison, SA; Lawitz, E; Torres, DM; Ward, JA, 2010) |
| "The initial treatment of chronic hepatitis C with nitazoxanide used 12 weeks of nitazoxanide monotherapy before combination therapy with peginterferon with or without ribavirin." | ( Elfert, A; Keeffe, EB; Rossignol, JF, 2010) |
| "In addition, treatment of chronic hepatitis C with peginterferon plus nitazoxanide without ribavirin is promising and requires further study." | ( Elfert, A; Keeffe, EB; Rossignol, JF, 2010) |
| "Antiviral treatment for chronic hepatitis C may be less effective if patients are co-infected with human immunodeficiency virus (HIV)." | ( Awad, T; Gluud, LL; Iorio, A; Marchesini, E, 2010) |
| "- The development of new drugs for the treatment of chronic hepatitis C represents a promising perspective also for HIV positive patients." | ( Rockstroh, JK; Vogel, M, 2009) |
| "Standard treatment of chronic hepatitis C (CHC) is peginterferon alfa (PEG-IFN alfa) plus ribavirin (RBV) for 48 weeks in patients infected with genotype 1, and 24 weeks for those infected with genotype 2 or 3." | ( Poordad, F; Zeuzem, S, 2010) |
| "We investigated consecutive treatment-naïve chronic hepatitis C patients at our center to examine the efficacy of treatment with pegylated interferon plus ribavirin in clinical routine." | ( Fuchsteiner, H; Hackl, F; Luger, C; Maieron, A; Metz-Gercek, S; Mittermayer, H; Schöfl, R; Ziachehabi, A, 2010) |
| "The current standard therapy for the treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, although many patients fail to clear the virus and their retreatment options are still unsatisfactory." | ( Andreone, P; Bernardi, M; Cannoletta, F; Cursaro, C; Di Donato, R; Fortini, C; Gramenzi, A; Grandini, E; Loggi, E; Riili, A; Scuteri, A, 2010) |
| "The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period." | ( Jung, EU; Kang, HG; Lee, SH; Lee, YJ; Moon, SS; Park, SJ; Seo, JA; Seol, SY, 2010) |
| "In patients with untreated genotype 1 chronic hepatitis C infection, the addition of the direct-acting antiviral agent boceprevir to standard treatment with peginterferon and ribavirin after a 4-week lead-in seems to have the potential to double the sustained response rate compared with that recorded with standard treatment alone." | ( Albrecht, JK; Anderson, FH; Brass, CA; Chaudhri, E; Davis, MN; Galati, JS; Gordon, SC; Jacobson, IM; Koury, K; Kwo, PY; Lawitz, EJ; McCone, J; Pedicone, LD; Pound, D; Ravendhran, N; Rossaro, L; Rubin, R; Schiff, ER; Vierling, JM, 2010) |
| "The objective of treatment for chronic hepatitis C is to prevent in the long term the complications and death that this disease may cause." | ( Daruich, J, 2010) |
| "To study individualized treatment of chronic hepatitis C (CHC) genotype 1 patients using respond guided therapy (RGT) of peginterferon α-2a in combination with ribavirin." | ( Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD, 2010) |
| "Interferon-α is used to treat chronic hepatitis C." | ( Abate, G; Bertino, G; Boemi, P; Calvagno, GS; Di Pino, A; Giancarlo, C; Ignaccolo, L; Judica, A; Maiorca, D; Mastrosimone, G; Mauceri, B; Misseri, M; Neri, S; Palermo, F; Petralia, A; Rizzotto, A; Vadalà, G, 2010) |
| "Results of treatments for chronic hepatitis C virus are only estimated and disclosed from pivotal trials." | ( Cadranel, JF; Denis, J; Duprat, C; Faroux, R; Lahmek, P; Morin, T; Nalet, B; Pariente, A; Renou, C, 2010) |
| "The standard treatment of chronic hepatitis C, pegylated interferon and ribavirin (pegI/R), has many limitations in both effectiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients." | ( Adán-Merino, L; Castillo-Grau, P; Gea-Rodríguez, F; Martín-Arranz, E; Olveira-Martín, A; Prados, C; Sáenz, JC; Segura-Cabral, JM, 2010) |
| "Evidence on the efficacy of antiviral treatment in chronic hepatitis C (CHC) patients with hepatocellular carcinoma (HCC) after curative treatment is scarce." | ( Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yeh, ML; Yu, ML, 2011) |
| "Type I interferon (IFN) is used for the treatment of chronic hepatitis C virus (HCV) infection." | ( Abe, H; Aimitsu, S; Chayama, K; Hayashida, Y; Hayes, CN; Hiraga, N; Imamura, M; Kao, JH; Kawakami, Y; Kubo, M; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T, 2011) |
| "The standard of care treatment for chronic hepatitis C viral infection (HCV) is a combination of pegylated interferon alfa and ribavirin for 24-48 weeks according to the virus genotype." | ( Abbacchi, A; Adewuyi, SA; Debold, C; Hong, BA; Lisker-Melman, M; North, CS; Pollio, DE, 2011) |
| "Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon-α and ribavirin." | ( Pawlotsky, JM, 2011) |
| "Adverse events attributed to the treatment of chronic hepatitis C patients with pegylated interferon (PEG-IFN) and ribavirin have been widely discussed." | ( Garcia, GF; Garib, JR; Silva, Fd; Teixeira, R, 2011) |
| "Until now, treatment of chronic hepatitis C consisted of the combination of peginterferon-α plus ribavirin, which provided limited rates of cure and was associated with frequent side effects." | ( Barreiro, P; Fernandez-Montero, JV; Labarga, P; Martin-Carbonero, L; Poveda, E; Soriano, V; Vispo, E, 2011) |
| "The standard of treatment of chronic hepatitis C is pegylated interferon and ribavirin." | ( Pawłowska, M, 2011) |
| "An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R)." | ( Abate, ML; Ahlenstiel, G; Armstrong, NJ; Bassendine, M; Berg, T; Bochud, PY; Booth, DR; Dore, GJ; Dunn, D; Gaudieri, S; George, J; Hammond, E; Hellard, M; Irving, WL; Mallal, S; Matthews, G; Müller, T; Nattermann, J; Negro, F; O'Connor, KS; Powell, E; Riordan, S; Sheridan, D; Smedile, A; Spengler, U; Stewart, GJ; Suppiah, V; Weltman, M, 2011) |
| "For the treatment of chronic hepatitis C, a combination of pegylated interferon-α (PEG-IFNα) and ribavirin has been widely used as a standard of care." | ( Hagiwara, H; Hayashi, N; Higashitani, K; Hiramatsu, N; Iio, S; Inoue, M; Kakita, N; Kanto, T; Kasahara, A; Katayama, K; Matsubara, T; Mita, E; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T, 2012) |
| "Neutropenia is frequent during treatment of chronic hepatitis C (CHC) with peginterferon and ribavirin." | ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2011) |
| "Interferon-alpha is used to treat chronic hepatitis C infections." | ( Chammas, MC; Danilovic, DL; Marui, S; Mendes-Correa, MC; Zambrini, H, 2011) |
| "Application of interferon in the treatment of chronic hepatitis C increases the frequency their occurrence." | ( Gołabek, V; Kupś-Rzepecka, J; Woźniakowska-Gesicka, T, 2011) |
| "The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-α (PEG-IFNα) and ribavirin (RBV)." | ( Mizokami, M; Nakanishi, M; Sugiyama, M; Tanaka, Y; Wakita, T, 2011) |
| "Boceprevir- and telaprevir-based treatments for chronic hepatitis C virus (HCV) infection use specific response-guided therapy (RGT) guidelines." | ( Harrington, PR; Naeger, LK; Zeng, W, 2012) |
| "The current treatment of Chronic Hepatitis C (CHC) is based on the combination of peginterferon alpha 2a or 2b and ribavirin." | ( Buti, M; Homs, M, 2012) |
| "The current treatment of chronic hepatitis C is based on pegylated alpha interferon (PEG-IFN-α) and ribavirin." | ( Baron, A; Brochot, E; Capron, D; Castelain, S; Coulouarn, C; Descamps, V; Duchaussoy, I; Duverlie, G; François, C; Nguyen-Khac, E, 2012) |
| "Today is a normal option to treat chronic hepatitis C as early as possible according to certain criteria." | ( Bali, D; Cullufi, P; Dervishi, E; Durro, V; Velmishi, V, 2012) |
| "Currently, the gold standard for the treatment of chronic hepatitis C is combination therapy with pegylated interferon alpha and ribavirin." | ( Habalová, V; Kristian, P; Schréter, I; Válková, I, 2011) |
| "According to recent experiences in the treatment of chronic hepatitis C in children and adolescents, a combination of PEG-interferon α with ribavirin has been found to be well tolerated and highly efficacious, particularly in individuals with genotype 2/3." | ( Wirth, S, 2012) |
| "In addition, treatment of chronic hepatitis C will become more complex." | ( , 2012) |
| "The current standard treatment of chronic hepatitis C, consisting of the combination of pegylated interferon-α (peginterferon) and ribavirin, lasts 24-48 weeks, and is accompanied by significant side effects and has a suboptimal chance of success." | ( Aronson, SJ; de Bruijne, J; Reesink, HW; Schinkel, J; van der Valk, M; Weegink, CJ, 2012) |
| "In the last decades, results of treatment for chronic hepatitis C have improved substantially." | ( Francque, S; Ho, E; Michielsen, P, 2012) |
| "Successful treatment of chronic hepatitis C may modulate drug hepatotoxicity, as it is associated with a decline in hepatic enzyme release and halts fibrosis progression in HIV/HCV-coinfected patients." | ( Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Krastinova, E; Perronne, C; Piroth, L; Pol, S; Quertainmont, Y; Rosenthal, E, 2012) |
| "For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin." | ( Pearlman, BL, 2012) |
| "Today, treatment of chronic hepatitis C is based on a synergistic combination of pegylated interferon and ribavirin with antiprotease inhibitors." | ( Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN, 2012) |
| "A 62-year-old woman being treated for chronic hepatitis C and high blood pressure was shown by computed tomography to have tumors in the lateral and medial segments of her liver, and in her right breast." | ( Akashi, M; Fujii, T; Inoue, Y; Momosaki, S; Nakayama, Y; Nishida, R; Saitsu, H; Shirouzu, K; Takahashi, H; Takahashi, R; Takami, Y; Takayoshi, K; Uchino, K, 2012) |
| "Antiviral treatment of chronic hepatitis C is not invariably successful, costly and associated with serious side-effects, and therefore should be indicated only when the chances of benefitting patients exceed the potential risks." | ( Bochud, PY; Clément, S; Conzelmann, S; Dill, MT; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pascarella, S; Pawlotsky, JM; Rubbia-Brandt, L; Zeuzem, S, 2013) |
| "We included 145 consecutive, treatment-naive chronic hepatitis C patients (mean age 47." | ( Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M, 2013) |
| "The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which is defined as exhibiting undetectable hepatitis C virus (HCV) RNA levels in serum following therapy for at least six months." | ( Corvino, SM; Grotto, RM; Padovani, JL; Pardini, MI; Silva, GF; Zeminian, LB, 2013) |
| "Interferon alfa remains the central treatment for chronic hepatitis C virus (HCV) infection." | ( Anty, R; Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Pop, S; Tran, A; Trucchi, R; Tsilika, K, 2013) |
| "To report our experience in the treatment of chronic hepatitis c and determine the predictive factors of sustained virologic response." | ( Abdelli, N; Ben Abdallah, H; Bizid, S; Bouali, R; Kilani, I; Mohamed, G, 2013) |
| "From 744 patients treated for chronic hepatitis C at our institution, 4 became HCV-RNA-positive again between weeks 36 and 48 post-treatment." | ( Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Plaza, Z; Poveda, E; Soriano, V; Treviño, A; Vispo, E, 2013) |
| "Interferon treatment for chronic hepatitis C is associated with non-specific symptoms including fever." | ( Han, H; Hoofnagle, JH; Liang, TJ; Noureddin, M; Park, YJ; Rotman, Y; Witthaus, M, 2013) |
| "Recommended treatment of chronic Hepatitis C virus (HCV) infection is interferon and ribavirin." | ( Ahmed, Wu; Alam, SE; Arif, A; Sajjad, SF; Waquar, J, 2012) |
| "The standard treatment for chronic hepatitis C virus (HCV) infection in HIV-infected subjects is the combination of alfapeginterferon (PEG-IFN) plus ribavirin." | ( Amendola Pires, MM; Barcaui, HS; Barroso, PF; Brandão-Mello, CE; May, SB; Tavares, GC, 2013) |
| "To optimize standard treatment of chronic hepatitis C in responder patients who have achieved undetectable viral load, a prospective study was conducted to determine the factors and kinetics of virologic relapse." | ( Brochot, E; Duverlie, G; Guillemard, C; Mathurin, P; Nguyen-Khac, E; Plantier, JC; Riachi, G; Vabret, A, 2013) |
| "nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients." | ( Armienta-Sarabia, R; Cordero-Pérez, P; Hernández-Gómez, ME; Malé-Velázquez, R; Marín-López, E; Muñoz-Espinosa, LE; Núñez-Camarena, Jde J; Olivera-Martínez, MA; Sánchez-Avila, JF; Torres-González, L, 2013) |
| "Recent advances in treatment of chronic hepatitis C virus have improved significantly due to the introduction of two new protease inhibitors-telaprevir and boceprevir." | ( Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC, 2013) |
| "Drug-drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of direct-acting anti-virals (DAAs)." | ( Calle Serrano, B; Cornberg, M; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Sollik, L; Wedemeyer, H, 2013) |
| "A challenge to the treatment of chronic hepatitis C with direct-acting antivirals is the emergence of drug-resistant hepatitis C virus (HCV) variants." | ( Berger, KL; Böcher, WO; Cartier, M; Datsenko, Y; Kukolj, G; Marquis, M; Massariol, MJ; Scherer, J; Steinmann, G; Stern, JO; Triki, I, 2014) |
| "Interferon-based treatment of chronic hepatitis C virus (HCV) infection can negatively affect patient-reported outcomes (PROs) and work productivity (WP)." | ( Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM, 2014) |
| "Results of treatment of chronic hepatitis C (CHC) with pegylated interferon plus ribavirin (PEG-RBV) are mainly available from well-designed clinical trials, and only few 'real-life' studies which give a true picture of success of therapy are available." | ( Goyal, O; Hissar, S; Khanna, P; Midha, V; Sharma, SK; Sood, A, 2014) |
| "The diagnosis and treatment of chronic hepatitis C are major concerns in prisons." | ( Antón, J; de Juan, J; Faraco, I; García-Guerrero, J; Marco, A; Portilla, J; Pozo, E; Saiz de la Hoya, P, 2014) |
| "Therefore, national guidelines for the treatment of chronic hepatitis C genotype 1 have been updated to include new and more efficient therapeutic options." | ( Duvnjak, M; Kurelac, I; Vince, A, 2013) |
| "In untreated genotype 1b chronic hepatitis C patients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy." | ( Bruno, R; Bruno, S; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A, 2014) |
| "We report a case of a 43-year-old man treated for chronic hepatitis C infection complicated by decompensated right heart failure diagnosed with PAH and external coronary artery compression secondary to a dilated pulmonary trunk." | ( Anderson, RD; Burns, AT; Thompson, A, 2014) |
| "The gold standard treatment for chronic hepatitis C virus (HCV) infection is pegylated interferon (PEG-IFN) in combination with ribavirin." | ( Ali, K; Aziz, H; Gill, ML; Irfan, J; Khattak, JZ; Raza, A, 2015) |
| "Within the last few years, treatment of chronic hepatitis C infection has progressed beyond regimens containing the first-wave direct-acting antiviral agents (DAAs) boceprevir and telaprevir, which had high pill burdens as well as low efficacy and safety in treatment-experienced patients." | ( Jensen, DM; Welch, NM, 2015) |
| "If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death." | ( Kattakuzhy, S; Kottilil, S; Levy, R, 2015) |
| "Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide." | ( Appourchaux, K; Asselah, T; Bièche, I; Boyer, N; Carrat, F; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Vidaud, M, 2015) |
| "Despite the rapid progress in treatment, chronic hepatitis C virus (HCV) infection remains a growing cause of liver-related mortality globally." | ( Feld, JJ; Sharma, SA, 2015) |
| "To decide when and how to treat children with chronic hepatitis C is an ongoing debate." | ( Ali, E; El Sherbini, A; Mostafa, S, 2015) |
| "There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease." | ( Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD, 2015) |
| "The role of interleukin (IL) 28B in the treatment of chronic hepatitis C (CHC) has recently been examined in many studies, while a possible relationship between IL28B and the presence of mixed cryoglobulinemia (MC) remains to be clarified." | ( Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G, 2015) |
| "Despite considerable progress in the treatment of chronic hepatitis C, many countries do not have access to these new treatments." | ( Besma, YL; Brochot, E; Gazouani, E; Morel, V; Mouelhi, L; Sghaier, I, 2015) |
| "Under-recognition and under-treatment of chronic hepatitis C virus (HCV) infection is an important determinant of the disease outcome." | ( Bae, SH; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, YS; Lee, HC; Lee, SS; Lee, YJ, 2016) |
| "Therefore, treatment of chronic hepatitis C should be prioritized in HIV/HCV-coinfected patients regardless of any liver fibrosis staging." | ( Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Soriano, V, 2016) |
| "New regimens for the treatment of chronic hepatitis C virus (HCV) genotype 3 have demonstrated substantial improvement in sustained virologic response (SVR) compared with existing therapies, but are considerably more expensive." | ( Goeree, R; Martel, MJ; Moshyk, A; Tahami Monfared, AA, 2016) |
| "There has been a revolution in the treatment of chronic hepatitis C." | ( Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D, 2016) |
| "The therapeutic landscape for the treatment of chronic hepatitis C virus infection has been rapidly evolving, and by 2016 there will be six approved, all-oral regimens for use in patients in the USA and most of Western Europe." | ( Nelson, DR; Peter, J, 2016) |
| "The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions." | ( Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015) |
| "Ninety-two treatment-naive chronic hepatitis C patients were treated with 24 or 48 weeks of peginterferon/ribavirin therapy according to their viral genotypes." | ( Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Lu, MY; Wang, SC; Yeh, ML; Yu, ML, 2016) |
| "We report good results of treatment for chronic hepatitis C virus genotype 1b -infected patients on hemodialysis with all oral DAAs (daclatasvir and asunaprevir)." | ( Miyagi, K; Miyazaki, R, 2016) |
| "In deciding to treat children with chronic hepatitis C virus, considerations should include both deferring treatment in patients during optimal growth periods, and the possibility that interferon-free regimens may be available to children in the next 5 to 10 years." | ( Albrecht, JK; Alonso, E; Ciocca, M; Gonzalez, T; Goodman, Z; Haber, B; Jackson, B; Lacaille, F; Lang, T; Noviello, S; Pedreira, A; Rodriguez-Baez, N; Yang, Z, 2017) |
| "The current standard treatment of chronic hepatitis C in Bosnia and Herzegovina consists of pegylated interferon alpha in combination with ribavirin." | ( Banjac, V; Miskovic, M; Zivlak-Radulovic, N, 2016) |
| "Advances in the treatment of chronic hepatitis C (HCV) have given HCV providers access to treatment regimens able to achieve sustained virological response (SVR or 'cure') in the majority of patients." | ( Flemming, JA; Lowe, CE, 2016) |
| "Significant progression in the treatment of chronic hepatitis C virus has been made with the introduction of direct-acting antivirals (DAAs)." | ( Davis, MM; Johnson, SW; Priest, DH; Stever, LM, 2016) |
| "Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited because of the risk for allograft rejection and poor tolerability." | ( Aghemo, A; Bourlière, M; Brainard, DM; Colombo, M; Dvory-Sobol, H; Hyland, R; Liu, H; Manns, M; Massetto, B; McHutchison, JG; Peck-Radosavljevic, M; Pol, S; Yun, C; Zhang, J, 2017) |
| "Recently, the treatment of chronic hepatitis C has markedly advanced." | ( Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Komeda, Y; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Watanabe, T, 2017) |
| "Currently, the standard regimen for the treatment of chronic hepatitis C in China is the PR regimen, namely pegylated interferon combined with ribavirin; however, there are still many shortcomings in this regimen." | ( Hu, P; Ren, H, 2016) |
| "Presently, no data exist for the treatment of chronic hepatitis C virus with ledipasvir/sofosbuvir (LDV/SOF) in an individual with a history of gastric bypass." | ( Griffin, SM; Johnson, SW; Teachey, AL; Valanejad, SM; Weber, SF, 2017) |
| "A total of 1809 treatment-naïve chronic hepatitis C virus (HCV) patients (829 HCV genotype 1 [G1] and 980 HCV G2) treated with PegIFN/RBV therapies were linked to the National Health Insurance Research Database, covering the entire population of Taiwan from 1998 to 2013 to collect the total medical-care expenses of outpatient (antiviral agents, nonantiviral agents, laboratory, and consultation costs) and inpatient (medication, logistic, laboratory, and intervention costs) visits." | ( Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Tsai, YS; Yeh, ML; Yu, ML, 2017) |
| "We investigated its efficacy in the treatment of chronic hepatitis C via a meta-analysis of randomised controlled trials." | ( Kim, HB; Lee, YJ; Myung, SK; Park, BJ, 2018) |
| "New highly effective treatments for chronic hepatitis C virus (HCV) infection are now available, but safety and efficacy data on the use of anti-HCV therapies in patients with renal failure, particularly those requiring PD, remain limited." | ( Cole, J; Stark, JE, 2017) |
| "We hereby report our experience of treating chronic hepatitis C in patients with severe renal insufficiency with full dose sofosbuvir and NS5A inhibitors." | ( De, A; Kumar, P; Kumari, S; Singh, A; Singh, V, 2018) |
| "Data are sparse on treatment of chronic hepatitis C virus (HCV) in cancer patients." | ( Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA, 2019) |
| "Finding safe and effective treatments for chronic hepatitis C virus (HCV) infection in the elderly is of clinical interest given the comorbidities and associated polypharmacy in this population." | ( Asatryan, A; Asselah, T; Foster, GR; Kopecky-Bromberg, S; Lei, Y; Mensa, FJ; Trinh, R; Zadeikis, N, 2019) |
| "Interferon therapy is used as a line of treatment of chronic hepatitis C virus (HCV) in several areas of the world including Egypt." | ( Ahmed, NS; Aref, AM; Helal, TEA; Mahmoud, HA; Radwan, NA; Wahib, AA; Zaki, AM, 2019) |
| "Two hundred patients undergoing DAAs treatment for chronic hepatitis C with advanced fibrosis (F3- F4) were consecutively enrolled." | ( Azzaroli, F; Bacchi-Reggiani, ML; Bazzoli, F; Festi, D; Mazzella, G; Porro, A; Ravaioli, F; Simili, A, 2019) |
| "Direct-acting antiviral treatments for chronic hepatitis C virus (HCV) infection are generally safe; however, understanding the safety profile of each regimen is essential for their continued use." | ( Brown, DD; Haber, BA; Klopfer, SO; Kwo, P; Nangia, G; Reddy, KR; Robertson, MN; Vierling, JM, 2020) |
| "Interferon (IFN)-free regimens for the treatment of chronic hepatitis C have shown high rates of sustained virological response (SVR) and improved patient-reported outcomes (PROs)." | ( Fagundes, RN; Ferreira, LEVVC; Pace, FHL, 2020) |
| "Ribavirin has been used for 25 years to treat patients with chronic hepatitis C virus (HCV) infection; however, its antiviral mechanism of action remains unclear." | ( Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S; Weiland, O, 2020) |
| "After DAA treatment for chronic hepatitis C infection, peripheral monocyte subsets from patients who achieved sustained virological response (SVR) reduced compared to healthy control." | ( Andrade, TG; Azeredo, EL; Gandini, M; Lacerda, G; Leite, PEC; Medeiros, T; Rosário, NF; Saraiva, GDN; Silva, AA; Xavier, AR, 2020) |